Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 3/20 | 0.64 |
| ▸ | CYP1B1 | Q16678 | 8/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 4/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | PDE5A | O76074 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13435569 | 0.79 | CYP1A1 (0.62) | PRKDCCYP1B1CYP1A1CYP1A2KDM4E | |
| SCHEMBL31061133 | 0.79 | PRKDC (1.00) | PRKDCCYP1B1CYP1A1CYP1A2KDM4E | |
| SCHEMBL30987790 | 0.78 | KDM4E (0.60) | PRKDCCYP1B1CYP1A1CYP1A2KDM4E | |
| SCHEMBL2726345 | 0.77 | KMT2A (0.68) | PRKDCCYP1B1CYP1A1CYP1A2KDM4E | |
| SCHEMBL12325500 | 0.77 | KDM4E (0.63) | PRKDCCYP1B1CYP1A1CYP1A2KDM4E | |
| Alpha-Naphthoflavone SCHEMBL121594 | 0.77 | CYP1A1 (1.00) | PRKDCCYP1B1CYP1A1CYP1A2KDM4E | |
| Alpha-Naphthoflavone SCHEMBL29351090 | 0.77 | CYP1A1 (1.00) | PRKDCCYP1B1CYP1A1CYP1A2KDM4E | |
| SCHEMBL29689973 | 0.76 | KDM4E (1.00) | PRKDCCYP1B1CYP1A1CYP1A2KDM4E | |
| SCHEMBL8054422 | 0.76 | KDM4E (0.61) | PRKDCCYP1B1CYP1A1CYP1A2KDM4E | |
| SCHEMBL16736777 | 0.76 | PRKDC (0.73) | PRKDCCYP1B1CYP1A1CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10006904-B2 | Rapid quantitative assay to measure CFTR function in a primary intestinal culture model | UMC UTRECHT HOLDING B.V. (NL) | 2018-06-26 | — | — | US | disclosed |
| US-10006904-B2 | Rapid quantitative assay to measure CFTR function in a primary intestinal culture model | UMC UTRECHT HOLDING B.V. (NL) | 2018-06-26 | — | — | US | disclosed |
| US-20150011420-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150011420-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-01-08 | — | — | US | disclosed |
| US-7674823-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-20070238729-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-7226918-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| US-20040192687-A1 | Dna-pk inhibitors | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
| EP-1417196-A1 | DNA-PK INHIBITORS | Cancer Research Technology Limited (GB) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003024949-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192687-A1 | Dna-pk inhibitors | ATM, CHEK1, XRCC6 | PRKDC 92/4885CYP1B1 1026/4885CYP1A1 1053/4885 |
| US-20070238729-A1 | DNA-PK INHIBITORS | ATM, CHEK2, CHEK1 | PRKDC 212/4885CYP1B1 1027/4885CYP1A1 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.